Tags : TIVO-3

$AVEO Oncology Reports Results of Fotivda (tivozanib) in P-III TIVO-3 Study for Refractory Advanced or Metastatic Renal Cell Carcinoma (RCC)$

Pharma

AVEO Oncology Reports Results of Fotivda (tivozanib) in P-III TIVO-3

Vartika Singh February 19, 2019

Shots: The P-III TIVO-3 study involves assessing of Fotivda (tivozanib) vs sorafenib in 350 patients with refractory advanced or metastatic renal cell carcinoma (RCC) P-III TIVO-3 results: 44% improvement in […]readmore

Tags : TIVO-3

AVEO Oncology Reports Results of Fotivda (tivozanib) in P-III TIVO-3

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : TIVO-3

﻿AVEO Oncology Reports Results of Fotivda (tivozanib) in P-III TIVO-3

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

AVEO Oncology Reports Results of Fotivda (tivozanib) in P-III TIVO-3